We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > HemaCare

News List

Charles River Laboratories wraps up $380m acquisition of HemaCare pharmaceutical-business-review
January 09, 2020
Charles River Laboratories International has wrapped up its $380m acquisition of HemaCare, a California-based human-derived cellular products provider for the cell therapy market.
Charles River Laboratories to buy HemaCare for $380m pharmaceutical-business-review
December 20, 2019
Charles River Laboratories International has agreed to acquire human-derived cellular products provider HemaCare for around $380m in cash.
Charles River Laboratories to acquire HemaCare for $380m pharmaceutical-technology
December 18, 2019
Charles River Laboratories International has signed a definitive agreement to acquire cellular products developer HemaCare for a cash consideration of approximately $380m.
HemaCare provides human derived biological material to China biospectrumasia
August 28, 2019
New distribution partnership allows high-quality human primary cells to reach the Chinese market